Evidence map›Paper›PMID 31737687›Full record

ArticleJournal of immunology research2019

Immunoregulatory Effects of Subcutaneous Immunotherapy on Lymphocyte Subgroups and Cytokines in Children with Asthma.

Yu-Ting He, Ying Zhou, Qi Shao, Cong Gan, Meng Chen, Yu-Ling Bao, Hai-Yan Gu, Shu-Lan Zhang, Yubao Cui, Man Tian

Open access · goldAbstract read
In one paragraph

Article in Journal of immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yu-Ting HeRespiratory Department, Children's Hospital of Nanjing Medical University, Nanjing, 210008 Jiangsu Province, China.
Ying ZhouDepartment of Pediatrics Laboratory, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi 214023, China.
Qi ShaoRespiratory Department, Children's Hospital of Nanjing Medical University, Nanjing, 210008 Jiangsu Province, China.
Cong GanRespiratory Department, Children's Hospital of Nanjing Medical University, Nanjing, 210008 Jiangsu Province, China.
Meng ChenRespiratory Department, Children's Hospital of Nanjing Medical University, Nanjing, 210008 Jiangsu Province, China.ORCID https://orcid.org/0000-0002-2812-2750
Yu-Ling BaoRespiratory Department, Children's Hospital of Nanjing Medical University, Nanjing, 210008 Jiangsu Province, China.
Hai-Yan GuRespiratory Department, Children's Hospital of Nanjing Medical University, Nanjing, 210008 Jiangsu Province, China.
Shu-Lan ZhangRespiratory Department, Children's Hospital of Nanjing Medical University, Nanjing, 210008 Jiangsu Province, China.
Yubao CuiDepartment of Clinical Laboratory, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi 214023, China.ORCID https://orcid.org/0000-0001-7736-8012
Man TianRespiratory Department, Children's Hospital of Nanjing Medical University, Nanjing, 210008 Jiangsu Province, China.ORCID https://orcid.org/0000-0001-9857-5256
Second Affiliated Hospital of Nanjing Medical University · CNWuxi People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAsthma is a syndrome that incorporates many immune phenotypes. The immunologic effects of subcutaneous immunotherapy (SCIT) exerts on allergic asthma remain still largely unknown. Here, we investigated the effects of SCIT on cytokine production and peripheral blood levels of lymphocyte subtypes in children with mite-induced moderate and severe allergic asthma.

methodsThe study included 60 kids with mite-induced allergic asthma from 5 to 10 years old. All subjects had received antiasthmatic pharmacologic for 3 months at baseline. Half of the children were treated with SCIT combined with pharmacologic treatment named the SCIT group and the other half only with pharmacologic therapy named the no-SCIT group. Total asthma symptom score (TASS) and total medication score (TMS) were recorded. Flow cytometry was used to identify lymphocyte subtypes: type 2 innate lymphocytes (ILC2s), type 1 (Th1) and type 2 (Th2) helper T cells, T helper 17 (Th17) cells, and regulatory T (Treg) cells. ELISA, flow cytometry, and cytometric bead array were used to assess cytokines IL-13, IFN-

resultsBoth groups can significantly improve clinical symptoms in children with asthma. SCIT can significantly reduce asthma medication after 6 months of treatment. SCIT induced a significantly higher and progressive reduction in ILC2 percentage and IL-13 levels after 3 and 6 months of treatment compared with baseline and compared with no-SCIT patients. Significant differences were detected in the Th1/Th2 cell ratio and IFN-

conclusionSCIT is a promising option to reduce the percentage of ILC2 and regulate Th1/Th2 and Th17/Treg immune balance in the peripheral blood of children with asthma.

Indexed as

ImmunomodulationAsthmaChildCytokinesDesensitization, ImmunologicFemaleHumansImmunophenotypingLymphocytesMaleSeverity of Illness IndexT-Lymphocyte SubsetsCytokines

Identifiers

PMID31737687
PMCPMC6815992
OpenAlexW2979692449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.